Can cancer increase the white blood cell (WBC) count?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cancer and White Blood Cell Count Elevation

Yes, cancer can increase white blood cell (WBC) count through several mechanisms. This elevation in WBCs is an important clinical finding that can have implications for diagnosis, prognosis, and management of cancer patients.

Mechanisms of Cancer-Related WBC Elevation

Cancer can increase WBC count through multiple pathways:

  1. Direct bone marrow infiltration: Cancer cells, particularly in hematologic malignancies, can infiltrate the bone marrow and disrupt normal hematopoiesis 1.

  2. Cytokine production: Cancer cells may produce cytokines that lead to increased WBC production. Tumors can release proinflammatory cytokines (IL-1, IL-6, TNF-α) that stimulate WBC production 1.

  3. Paraneoplastic phenomenon: Some cancers can trigger a systemic inflammatory response as a paraneoplastic effect, leading to leukocytosis.

  4. Tumor necrosis: Tissue damage and necrosis from tumor growth can trigger inflammatory responses.

Clinical Significance of Elevated WBC in Cancer

Diagnostic Value

  • A rapidly increasing WBC count (increases of >10,000/μL within ≤3 months) in the absence of signs of active inflammation or infection may indicate disease progression in certain malignancies like chronic myelomonocytic leukemia (CMML) 1.

Prognostic Implications

  • Elevated pre-treatment WBC count has been identified as an independent negative prognostic factor in several cancer types 2.
  • In gastric cancer, higher pre-treatment total WBC count is an independent prognostic factor affecting overall survival 2.
  • In cancer patients with venous thromboembolism (VTE), elevated WBC count (>11,000 cells/μL) is associated with increased risk of VTE recurrence, major bleeding, and death 3.

Risk Assessment

  • Elevated WBC count (≥8.6 × 10^9 cells/L) measured prior to cancer development is associated with a 2.4-fold higher risk of venous thromboembolism in patients who later develop cancer 4.
  • Recent research from the UK Biobank shows that elevated WBC count is associated with increased risk of cancer overall (HR 1.05 per quartile increase) and specifically with chronic lymphocytic leukemia/small lymphocytic lymphoma, lung cancer, and breast cancer 5.

Types of WBC Elevations in Cancer

Different cancer types may cause different patterns of WBC elevation:

  • Neutrophilia: Common in solid tumors and associated with poor prognosis
  • Lymphocytosis: Seen in lymphoid malignancies
  • Monocytosis: Can occur in myelomonocytic leukemias and some solid tumors
  • Eosinophilia: Sometimes seen in lymphomas and certain solid tumors
  • Basophilia: May be present in myeloproliferative disorders

Clinical Approach to Elevated WBC in Cancer Patients

When evaluating elevated WBC count in a cancer patient:

  1. Rule out other causes:

    • Infection
    • Medications (corticosteroids, G-CSF)
    • Stress response
    • Splenectomy
  2. Assess pattern and degree of elevation:

    • Determine which WBC subtypes are elevated
    • Note the magnitude and rate of increase
  3. Consider implications for cancer management:

    • Need for more aggressive treatment
    • Risk of complications (e.g., thrombosis)
    • Potential for disease progression

Treatment Considerations

  • In cases of extreme leukocytosis (WBC >100 × 10^9/L), rapid cytoreduction may be necessary 6.
  • Options for cytoreduction include:
    • Hydroxyurea (1-2 weeks to 50% reduction)
    • Low-dose cytarabine (3-5 days to 50% reduction)
    • Leukapheresis (hours to 30-80% reduction) for emergent cases 6

Conclusion

White blood cell count elevation is a common finding in many cancer types and can result from direct and indirect effects of malignancy. The pattern, degree, and timing of WBC elevation can provide valuable diagnostic and prognostic information. Monitoring WBC count and its components is an important aspect of cancer patient management, particularly for assessing disease activity, progression risk, and treatment response.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

White Blood Cell Count, Neutrophil-to-Lymphocyte Ratio, and Incident Cancer in the UK Biobank.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2024

Guideline

Diagnosis and Management of Leukemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.